{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:57:56Z","timestamp":1787317076465,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.rpth.2023.100096","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T11:53:20Z","timestamp":1677498800000},"page":"100096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice"],"prefix":"10.1016","volume":"7","author":[{"given":"Gordon","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Seelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne C.","family":"Cannegieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel M.C.","family":"Hovens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van der Hulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge A.","family":"Trines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 J.","family":"Vlot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri H.","family":"Versteeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.W.","family":"Hemels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederikus A.","family":"Klok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2023.100096_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/2047487318759858","article-title":"CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer","volume":"25","author":"D\u2019Souza","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.rpth.2023.100096_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cam4.1054","article-title":"Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study","volume":"6","author":"Ording","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.rpth.2023.100096_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2018.07.138","article-title":"Patients with cancer and atrial fibrillation treated with doacs: a prospective cohort study","volume":"269","author":"Vedovati","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rpth.2023.100096_bib4","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial","volume":"7","author":"Fanola","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.rpth.2023.100096_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.blre.2019.03.005","article-title":"Atrial fibrillation and cancer - an unexplored field in cardiovascular oncology","volume":"35","author":"Chu","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2023.100096_bib6","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.100096_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaccao.2021.03.006","article-title":"Risk of atrial fibrillation according to cancer type: a nationwide population-based study","volume":"3","author":"Yun","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.rpth.2023.100096_bib8","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1002\/cam4.4105","article-title":"Prevalence, trends, and outcomes of atrial fibrillation in hospitalized patients with metastatic cancer: findings from a national sample","volume":"10","author":"Han","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.rpth.2023.100096_bib9","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study","volume":"127","author":"Pastori","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.rpth.2023.100096_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104560","article-title":"Risk of ischemic stroke and major bleeding in patients with atrial fibrillation and cancer","volume":"29","author":"Aspberg","year":"2020","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.rpth.2023.100096_bib11","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2023.100096_bib12","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2023.100096_bib13","first-page":"e125","volume":"140","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2023.100096_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2023.100096_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2023.100096_bib16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2023.100096_bib17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.100096_bib18","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.100096_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.100096_bib20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.rpth.2023.100096_bib21","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1161\/STROKEAHA.120.033470","article-title":"Clinical outcomes in atrial fibrillation patients with a history of cancer treated with non-vitamin K antagonist oral anticoagulants: a nationwide cohort study","volume":"52","author":"Chan","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2023.100096_bib22","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1002\/cam4.4012","article-title":"Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants","volume":"10","author":"Ording","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.rpth.2023.100096_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00228-021-03132-x","article-title":"Safety and efficacy of new oral anticoagulants compared to those of warfarin in AF patients with cancer: a meta-analysis of randomized clinical trials and observational studies","volume":"77","author":"Chen","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2023.100096_bib24","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jth.14478","article-title":"Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH","volume":"17","author":"Delluc","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100096_bib25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2020.03.005","article-title":"Anticoagulation in thrombocytopenic patients with hematological malignancy: a multinational clinical vignette-based experiment","volume":"77","author":"Leader","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rpth.2023.100096_bib26","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","article-title":"Anticoagulation strategies in patients with cancer: JACC review topic of the week","volume":"73","author":"Mosarla","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2023.100096_bib27","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2023.100096_bib28","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100096_bib29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ije\/22.3.369","article-title":"Completeness of cancer registration in Limburg, the Netherlands","volume":"22","author":"Schouten","year":"1993","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.rpth.2023.100096_bib30","first-page":"7","article-title":"Structural reforms and hospital payment in the Netherlands","volume":"3","author":"Tan","year":"2010","journal-title":"EuroObserver"},{"key":"10.1016\/j.rpth.2023.100096_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/heartjnl-2019-316305","article-title":"Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score","volume":"107","author":"Chu","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.rpth.2023.100096_bib32","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100096_bib33","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100096_bib34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100096_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejim.2018.10.012","article-title":"Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality","volume":"59","author":"Malavasi","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rpth.2023.100096_bib36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ehjqcco\/qcx004","article-title":"Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry","volume":"3","author":"Melloni","year":"2017","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.rpth.2023.100096_bib37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.breast.2019.05.017","article-title":"Current status of anticoagulation in patients with breast cancer and atrial fibrillation","volume":"46","author":"Pardo Sanz","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.rpth.2023.100096_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejim.2020.08.004","article-title":"Patterns of anticoagulation for atrial fibrillation in cancer patients referred to cardio-oncological evaluation","volume":"82","author":"Toma","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rpth.2023.100096_bib39","article-title":"Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke\u00a0and bleed in patients with and without anticoagulation","volume":"7","author":"Fox","year":"2017","journal-title":"BMJ\u00a0Open"},{"key":"10.1016\/j.rpth.2023.100096_bib40","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/eurjpc\/zwaa054","article-title":"Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management","volume":"28","author":"Boriani","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.rpth.2023.100096_bib41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100096_bib42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11239-020-02180-x","article-title":"Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"Weitz","year":"2020","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2023.100096_bib43","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","article-title":"Identifying patients at high risk for stroke despite anticoagulation: a\u00a0comparison of contemporary stroke risk stratification schemes in\u00a0an anticoagulated atrial fibrillation cohort","volume":"41","author":"Lip Gregory","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2023.100096_bib44","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of Apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2023.100096_bib45","article-title":"Risk stratification for bleeding complications in patients with venous thromboembolism: application of the HAS-BLED bleeding score during the first 6 months of anticoagulant treatment","volume":"7","author":"Brown","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.rpth.2023.100096_bib46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.rpth.2023.100096_bib47","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/j.thromres.2018.02.064","article-title":"Cancer diagnosis as a risk factor of ischemic stroke in atrial fibrillation patients with low stroke risk score","volume":"164","author":"Atterman","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2023.100096_bib48","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2023.100096_bib49","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2023.100096_bib50","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2023.100096_bib51","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.2019001605","article-title":"How I assess and manage the risk of bleeding in patients treated for venous thromboembolism","volume":"135","author":"Klok","year":"2020","journal-title":"Blood"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923000651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923000651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:26:02Z","timestamp":1762863962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037923000651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2475037923000651"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2023.100096","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2023.100096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"100096"}}